| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $513,046 ) |
| | 2025 | 2025 | BARUCH S. BLUMBERG INSTITUTE | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | U01CA275648 | Impact of preanalytic procurement and processing variables on the detection of HCC DNA in urine | 001 | 3 | NIH | 3/3/2025 | $331,171 |
| | 2025 | 2025 | BARUCH S. BLUMBERG INSTITUTE | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R21AI179930 | Chemically ligated-guide RNA (lgRNA)-based CRISPR/Cas9 gene editing for elimination of hepatitis B virus cccDNA | 000 | 2 | NIH | 12/3/2024 | $181,875 |
| | 2025 | 2024 | BARUCH S. BLUMBERG INSTITUTE | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | U01CA275648 | Impact of preanalytic procurement and processing variables on the detection of HCC DNA in urine | 000 | 2 | NIH | 12/4/2024 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $789,569 ) |
| | 2024 | 2024 | BARUCH S. BLUMBERG INSTITUTE | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | U01CA275648 | Impact of preanalytic procurement and processing variables on the detection of HCC DNA in urine | 001 | 2 | NIH | 4/17/2024 | $18,398 |
| | 2024 | 2024 | BARUCH S. BLUMBERG INSTITUTE | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | U01CA275648 | Impact of preanalytic procurement and processing variables on the detection of HCC DNA in urine | 000 | 2 | NIH | 1/25/2024 | $331,171 |
| | 2024 | 2024 | BARUCH S. BLUMBERG INSTITUTE | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R21AI179930 | Chemically ligated-guide RNA (lgRNA)-based CRISPR/Cas9 gene editing for elimination of hepatitis B virus cccDNA | 000 | 1 | NIH | 12/19/2023 | $240,000 |
| | 2024 | 2024 | BARUCH S. BLUMBERG INSTITUTE | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R21AI168792 | Liver Targeting Dihydroquinolizinone (DHQ) Molecules as Hepatitis B Virus Antivirals with Reduced Toxicity | 001 | 2 | NIH | 8/13/2024 | $200,000 |
| | 2024 | 2023 | BARUCH S. BLUMBERG INSTITUTE | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R21AI168792 | Liver Targeting Dihydroquinolizinone (DHQ) Molecules as Hepatitis B Virus Antivirals with Reduced Toxicity | 000 | 1 | NIH | 10/25/2023 | $0 |
| | 2024 | 2022 | BARUCH S. BLUMBERG INSTITUTE | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R01AI134732 | Development of Benzodiazepine YFV NS4B inhibitors as therapeutic agents for Yellow Fever | 000 | 5 | NIH | 1/18/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $634,150 ) |
| | 2023 | 2023 | BARUCH S BLUMBERG INSTITUTE | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R21AI168792 | Liver Targeting Dihydroquinolizinone (DHQ) Molecules as Hepatitis B Virus Antivirals with Reduced Toxicity | 000 | 1 | NIH | 9/22/2023 | $240,000 |
| | 2023 | 2023 | BARUCH S BLUMBERG INSTITUTE | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | U01CA275648 | Impact of preanalytic procurement and processing variables on the detection of HCC DNA in urine | 000 | 1 | NIH | 1/24/2023 | $395,418 |
| | 2023 | 2020 | BARUCH S. BLUMBERG INSTITUTE | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R21CA235139 | CCR5 inhibitors to enhance therapeutic response of breast cancer to DNA damaging agents | 000 | 1 | NIH | 4/17/2023 | $0 |
| | 2023 | 2020 | BARUCH S. BLUMBERG INSTITUTE | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R01CA202769 | Development of cell-free DNA assays for HCC screening and liquid biopsy | 000 | 5 | NIH | 4/19/2023 | -$1,268 |
|
| Issue Date FY: 2022 ( Subtotal = $680,797 ) |
| | 2022 | 2022 | BARUCH S. BLUMBERG INSTITUTE | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R01AI134732 | Development of Benzodiazepine YFV NS4B inhibitors as therapeutic agents for Yellow Fever | 000 | 5 | NIH | 4/29/2022 | $680,797 |
|
| Issue Date FY: 2021 ( Subtotal = $692,067 ) |
| | 2021 | 2021 | BARUCH S. BLUMBERG INSTITUTE | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R01AI134732 | Development of Benzodiazepine YFV NS4B inhibitors as therapeutic agents for Yellow Fever | 000 | 4 | NIH | 4/20/2021 | $692,067 |
| | 2021 | 2018 | BARUCH S. BLUMBERG INSTITUTE | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R01CA132115 | DACH1/Eya Cell fate determination factor and mammary tumorigenesis | 000 | 9 | NIH | 10/22/2020 | $0 |
| | 2021 | 2018 | BARUCH S. BLUMBERG INSTITUTE | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R01AI113267 | Evaluation of therapeutic benefits of HBV nucleocapsid assembly inhibitors | 000 | 6 | NIH | 5/17/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $1,496,830 ) |
| | 2020 | 2020 | BARUCH S. BLUMBERG INSTITUTE | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R01AI134732 | Development of Benzodiazepine YFV NS4B inhibitors as therapeutic agents for Yellow Fever | 000 | 3 | NIH | 3/27/2020 | $716,197 |
| | 2020 | 2020 | BARUCH S. BLUMBERG INSTITUTE | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R21CA235139 | CCR5 inhibitors to enhance therapeutic response of breast cancer to DNA damaging agents | 000 | 1 | NIH | 9/21/2020 | $382,756 |
| | 2020 | 2020 | BARUCH S. BLUMBERG INSTITUTE | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R01CA202769 | Development of cell-free DNA assays for HCC screening and liquid biopsy | 000 | 5 | NIH | 5/7/2020 | $397,877 |
| | 2020 | 2018 | BARUCH S. BLUMBERG INSTITUTE | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R01AI113267 | Evaluation of therapeutic benefits of HBV nucleocapsid assembly inhibitors | 000 | 6 | NIH | 8/27/2020 | $0 |
| | 2020 | 2017 | BARUCH S. BLUMBERG INSTITUTE | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R01AI104636 | A small molecule for management of filovirus hemorrhagic fevers | 000 | 6 | NIH | 1/7/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $1,109,579 ) |
| | 2019 | 2019 | BARUCH S. BLUMBERG INSTITUTE | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R01CA202769 | Development of cell-free DNA assays for HCC screening and liquid biopsy | 000 | 4 | NIH | 5/31/2019 | $385,939 |
| | 2019 | 2019 | BARUCH S. BLUMBERG INSTITUTE | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R01AI134732 | Development of Benzodiazepine YFV NS4B inhibitors as therapeutic agents for Yellow Fever | 000 | 2 | NIH | 3/27/2019 | $723,640 |
|
| Issue Date FY: 2018 ( Subtotal = $2,086,791 ) |
| | 2018 | 2018 | BARUCH S. BLUMBERG INSTITUTE | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R01CA132115 | DACH1/Eya Cell fate determination factor and mammary tumorigenesis | 002 | 9 | NIH | 8/16/2018 | $428,056 |
| | 2018 | 2018 | BARUCH S. BLUMBERG INSTITUTE | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R01AI113267 | Evaluation of therapeutic benefits of HBV nucleocapsid assembly inhibitors | 000 | 6 | NIH | 4/25/2018 | $537,218 |
| | 2018 | 2018 | BARUCH S. BLUMBERG INSTITUTE | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R01AI134732 | Development of Benzodiazepine YFV NS4B inhibitors as therapeutic agents for Yellow Fever | 000 | 1 | NIH | 4/27/2018 | $723,640 |
| | 2018 | 2018 | BARUCH S. BLUMBERG INSTITUTE | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R01CA202769 | Development of cell-free DNA assays for HCC screening and liquid biopsy | 000 | 3 | NIH | 5/15/2018 | $397,877 |
| | 2018 | 2017 | BARUCH S. BLUMBERG INSTITUTE | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R01CA132115 | DACH1/Eya Cell fate determination factor and mammary tumorigenesis | 001 | 8 | NIH | 8/15/2018 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $2,398,109 ) |
| | 2017 | 2017 | BARUCH S. BLUMBERG INSTITUTE | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R01CA132115 | DACH1/Eya Cell fate determination factor and mammary tumorigenesis | 001 | 8 | NIH | 7/13/2017 | $372,150 |
| | 2017 | 2017 | BARUCH S. BLUMBERG INSTITUTE | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R01CA202769 | Development of cell-free DNA assays for HCC screening and liquid biopsy | 000 | 2 | NIH | 5/19/2017 | $472,981 |
| | 2017 | 2017 | BARUCH S. BLUMBERG INSTITUTE | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R01AI113267 | Evaluation of therapeutic benefits of HBV nucleocapsid assembly inhibitors | 000 | 5 | NIH | 5/24/2017 | $511,927 |
| | 2017 | 2017 | BARUCH S. BLUMBERG INSTITUTE | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R01CA132115 | DACH1/Eya Cell fate determination factor and mammary tumorigenesis | 003 | 8 | NIH | 8/18/2017 | $55,906 |
| | 2017 | 2017 | BARUCH S. BLUMBERG INSTITUTE | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R01CA132115 | DACH1/Eya Cell fate determination factor and mammary tumorigenesis | 005 | 8 | NIH | 8/28/2017 | $4,201 |
| | 2017 | 2017 | BARUCH S. BLUMBERG INSTITUTE | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R01AI104636 | A small molecule for management of filovirus hemorrhagic fevers | 000 | 6 | NIH | 5/5/2017 | $980,944 |
|
| Issue Date FY: 2016 ( Subtotal = $1,891,047 ) |
| | 2016 | 2016 | INSTITUTE FOR HEPATITIS & VIRUS RESEARCH | 3805 OLD EASTON ROAD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R01AI113267 | Evaluation of therapeutic benefits of HBV nucleocapsid assembly inhibitors | 000 | 4 | NIH | 5/31/2016 | $578,621 |
| | 2016 | 2016 | INSTITUTE FOR HEPATITIS & VIRUS RESEARCH | 3805 OLD EASTON ROAD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R01CA202769 | Development of cell-free DNA assays for HCC screening and liquid biopsy | 000 | 1 | NIH | 5/30/2016 | $432,900 |
| | 2016 | 2016 | INSTITUTE FOR HEPATITIS & VIRUS RESEARCH | 3805 OLD EASTON ROAD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R01AI104636 | A small molecule for management of filovirus hemorrhagic fevers | 000 | 5 | NIH | 6/1/2016 | $879,526 |
|
| Issue Date FY: 2015 ( Subtotal = $1,880,198 ) (Continued on the next page) |
| | 2015 | 2015 | INSTITUTE FOR HEPATITIS & VIRUS RESEARCH | 3805 OLD EASTON ROAD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R01AI113267 | Evaluation of therapeutic benefits of HBV nucleocapsid assembly inhibitors | 002 | 3 | NIH | 5/15/2015 | $669,728 |
|
